“Myriad Genetics, Inc. MYGN -4.19% today presented new data from a clinical validation study of Prolaris at the 2014 American Urological Association (AUA) Annual Meeting in Orlando, Fla. The study is the largest validation study to date of any gene-based prognostic test in patients with prostate cancer who were diagnosed by needle biopsy. A key finding was that the Prolaris test accurately differentiated newly diagnosed patients who were likely to die from prostate cancer within 10 years from those with lower-risk disease, which should open the door to more appropriate clinical care for patients at all risk levels. Prolaris is a novel molecular diagnostic test that accurately predicts cancer-specific death and metastases in men with prostate cancer and is a much stronger indicator of clinical outcomes than Gleason score or PSA.”
Editor’s note: Learn more about personalized approaches to cancer treatment.
“Researchers believe that susceptibility to common diseases stems from a combination of common genetic variants and a variety of rare genetic mutations. But this only accounts for a small proportion of potential heritable risk factors for disease. Now, new research has discovered that some genetic variants could indicate the presence of rare genetic mutations that have yet to be discovered, which may contribute to the risk of common diseases.”
Editor’s Note: While this story is about genetics as it relates to cancer risk, genetics can also provide valuable information to guide treatment. Interested readers might look into the following tests, which are just a few of several molecular/genetic tests to guide prostate cancer treatment: Oncotype DX, Prolaris, and PCA3.